| I-01 Nurul Azrin Abd Rahman A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study Wednesday 09:50-11:15 |
| I-02 Mahmoud Abdelwahab Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis Wednesday 09:50-11:15 |
| I-03 Khaled Abduljalil Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice Wednesday 09:50-11:15 |
| I-04 Anson Abraham Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design? Wednesday 09:50-11:15 |
| I-05 Ahmad Abuhelwa Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression Wednesday 09:50-11:15 |
| I-06 Ahmed Aliyu Abulfathi External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package Wednesday 09:50-11:15 |
| I-07 Oliver Ackaert Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects Wednesday 09:50-11:15 |
| I-08 Bambang Adiwijaya Component score models of HAMD were more predictive than total score models Wednesday 09:50-11:15 |
| I-09 Jae Eun Ahn Longitudinal Model-Based Meta-Analysis for Liver Biomarkers and Biopsy Endpoints in Patients with Non-Alcoholic Fatty Liver Disease Wednesday 09:50-11:15 |
| I-10 Maurice Ahsman A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy Wednesday 09:50-11:15 |
| I-11 Marie Alexandre Modeling viral rebound in HIV therapeutic vaccine studies Wednesday 09:50-11:15 |
| I-12 Joachim Almquist Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation Wednesday 09:50-11:15 |
| I-13 Jokha AL-Qassabi Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment Wednesday 09:50-11:15 |
| I-14 Hesham Al-Sallami The use of a Bayesian dosing tool to optimise enoxaparin treatment: a pilot clinical study Wednesday 09:50-11:15 |
| I-15 Vincent Aranzana-Climent Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii Wednesday 09:50-11:15 |
| I-16 Million Arefayene Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011) Wednesday 09:50-11:15 |
| I-17 Leticia Arrington An R package for Automated Generation of Item Response Theory Model NONMEM Control File Wednesday 09:50-11:15 |
| I-18 Usman Arshad A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients Wednesday 09:50-11:15 |
| I-19 Muhammad Waqar Ashraf Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers Wednesday 09:50-11:15 |
| I-20 Magnus Åstrand nonmem2R: An R-package for Visual Predictive Checks and Goodness-of-fit Plots Wednesday 09:50-11:15 |
| I-21 Ioanna Athanasiadou Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis Wednesday 09:50-11:15 |
| I-22 Linda Aulin Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents Wednesday 09:50-11:15 |
| I-23 Rami Ayoun Alsoud Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy Wednesday 09:50-11:15 |
| I-24 Geraldine Celliere Straightforward dose adaptation simulations with Simulx, the simulator of the MonolixSuite Wednesday 09:50-11:15 |
| I-25 LE Ba Hai Population pharmacokinetic model of sorafenib and application to a case report Wednesday 09:50-11:15 |
| I-26 Junjie Ding Pharmacometric drug adherence approach and its application in a clinical setting Wednesday 09:50-11:15 |
| I-27 Vanessa Baier Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism Wednesday 09:50-11:15 |
| I-28 Pavel Balazki A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models. Wednesday 09:50-11:15 |
| I-29 Violeta Balbas-Martinez Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease Wednesday 09:50-11:15 |
| I-30 Irina Baltcheva ggPMX: an open-source R package for pharmacometric model diagnostic plots Wednesday 09:50-11:15 |
| I-31 Maddlie Bardol Population pharmacokinetics of fentanyl in very preterm infants Wednesday 09:50-11:15 |
| I-32 Christian Bartels Getting a better description of treatment effects for time to event data using PKPD modelling Wednesday 09:50-11:15 |
| I-33 Roberta Bartolucci Optimal design of paediatric clinical trials: the Macitentan case study Wednesday 09:50-11:15 |
| I-34 Carla Bastida Fernández Assessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients Wednesday 09:50-11:15 |
| I-35 Francesco Bellanti Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs Wednesday 09:50-11:15 |
| I-36 Amina Bensalem Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis Wednesday 09:50-11:15 |
| I-37 Linnea Bergenholm Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data Wednesday 09:50-11:15 |
| I-38 Aliénor Bergès Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case Wednesday 09:50-11:15 |
| I-39 Martin Bergstrand Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling Wednesday 09:50-11:15 |
| I-40 Jan Berkhout Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia Wednesday 09:50-11:15 |
| I-41 Julie Bertrand Model-based approach for group sequential and adaptive designs in parallel and cross-over bioequivalence studies Wednesday 09:50-11:15 |
| I-42 Robert Bies On the Multilemma of reproducibility: Stochastic or Deterministic or Stochastic and Deterministic Wednesday 09:50-11:15 |
| I-43 Bruno Bieth Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer Wednesday 09:50-11:15 |
| I-44 Roberto Bizzotto Conditional linear mixed-effect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study Wednesday 09:50-11:15 |
| I-45 Irina Bondareva Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data Wednesday 09:50-11:15 |
| I-46 Guillaume Bonnefois A new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies Wednesday 09:50-11:15 |
| I-47 Elisa Borella Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia Wednesday 09:50-11:15 |
| I-48 Agnieszka Borsuk-De Moor The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits Wednesday 09:50-11:15 |
| I-49 Thomas Bouillon Model predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation. Wednesday 09:50-11:15 |
| I-50 Marion Bouillon-Pichault Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma Wednesday 09:50-11:15 |
| I-51 Muriel Boulton What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)? Wednesday 09:50-11:15 |
| I-52 Ari Brekkan Viggosson Model based support to biosimilarity assessment planning – A case study of pegfilgrastim Wednesday 09:50-11:15 |
| I-53 Astrid Broeker Parameter uncertainty in small datasets – evaluation approaches at their limit Wednesday 09:50-11:15 |
| I-54 Vincent Buchheit Data scientists for improving efficiency and quality of quantitative clinical pharmacology analyses Wednesday 09:50-11:15 |
| I-55 Núria Buil Bruna Can monocyte counts predict future drug-induced neutropenia toxicities? Wednesday 09:50-11:15 |
| I-56 David Busse Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling Wednesday 09:50-11:15 |
| I-57 Antonio Cabal Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery Wednesday 09:50-11:15 |
| I-58 Unai Caballero Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris Wednesday 09:50-11:15 |
| I-59 Elisa Calvier Alirocumab population pharmacokinetics in Chinese patients using priors Wednesday 09:50-11:15 |
| I-60 Tim Cardilin Tumor Static Exposure for anticancer combinations in early drug discovery Wednesday 09:50-11:15 |
| I-61 Fernando Carreño Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia Wednesday 09:50-11:15 |
| I-62 Jantine Brussee Model-based dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults Wednesday 09:50-11:15 |
| I-63 Blesson Chacko Why patients may not benefit from effective oncology drugs Wednesday 09:50-11:15 |
| I-64 Dong Woo Chae Predictive model of postoperative nausea and vomiting in patients treated with Fentanyl-based intravenous patient controlled analgesia Wednesday 09:50-11:15 |
| I-65 Anne Chain A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia Wednesday 09:50-11:15 |
| I-66 Anna Chan Kwong Bridging studies: handling covariates models using the Prior approach Wednesday 09:50-11:15 |
| I-67 Christophe Chassagnole A precision dosing application for docetaxel in metastatic prostate cancer Wednesday 09:50-11:15 |
| I-68 Estelle Chasseloup Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data Wednesday 09:50-11:15 |
| I-69 Jonathan Chauvin Novel user-friendly applications for dose individualization of sunitinib and imatinib Wednesday 09:50-11:15 |
| I-70 Alexia Chauzy Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria Wednesday 09:50-11:15 |
| I-71 Viji Chelliah Mechanistic models of cancer-immune cycle and immunotherapies Wednesday 09:50-11:15 |
| I-72 Lu Chen Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis Wednesday 09:50-11:15 |
| I-73 Maxwell Chirehwa Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients Wednesday 09:50-11:15 |
| I-74 Siri Kalyan Chirumamilla Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients Wednesday 09:50-11:15 |
| I-75 Palang Chotsiri Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity Wednesday 09:50-11:15 |
| I-76 Emmanuelle Comets Conditional non-parametric bootstrap for non-linear mixed effect models Wednesday 09:50-11:15 |
| I-77 Valerie Cosson Target-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy Wednesday 09:50-11:15 |
| I-78 Perrine Courlet Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV. Wednesday 09:50-11:15 |
| I-79 Sinziana Cristea Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiology-based pharmacokinetics approach Wednesday 09:50-11:15 |
| I-80 Salvatore D'Agate Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Pre-term Neonates Wednesday 09:50-11:15 |
| I-81 Kim Dao Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells Wednesday 09:50-11:15 |
| I-82 Mailys De Sousa Mendes Transporter inhibition: modelling in-vitro Transwell assays Wednesday 09:50-11:15 |
| I-83 Eva Maria del Amo Paez Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes Wednesday 09:50-11:15 |
| I-84 Francesca Del Bene Intratympanic drug administration: a challenge for PK modelling Wednesday 09:50-11:15 |
| I-85 Laurence Del Frari Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures Wednesday 09:50-11:15 |
| I-86 Oleg Demin Jr Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling Wednesday 09:50-11:15 |
| I-87 Laure Deyme Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue Wednesday 09:50-11:15 |
| I-88 Sofie Dhaese The use of optimal experimental design to inform a clinical trial on non-linearity of piperacillin clearance in critically ill patients. Wednesday 09:50-11:15 |
| I-89 Richard Dimelow PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously Wednesday 09:50-11:15 |
